Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Elevation in Serum Troponin I Predicts the Benefit of Tirofiban

Elevation in Serum Troponin I Predicts the Benefit of Tirofiban Background: Elevations in serum troponins among patients with acute coronary syndromes have been shown to identify those patients who are at high risk for poor outcome and who accrue larger relative benefits from aggressive antiplatelet and antithrombotic therapies. We studied a group of patients from the PRISM-PLUS trial to explore whether simply using serum troponin I, a serum marker of cardiac injury, could predict benefit of GP IIb/IIIa receptor antagonism with tirofiban. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thrombosis and Thrombolysis Springer Journals

Elevation in Serum Troponin I Predicts the Benefit of Tirofiban

Loading next page...
 
/lp/springer-journals/elevation-in-serum-troponin-i-predicts-the-benefit-of-tirofiban-RpOSJe2YsN

References (20)

Publisher
Springer Journals
Copyright
Copyright © 2001 by Kluwer Academic Publishers
Subject
Medicine & Public Health; Cardiology; Hematology
ISSN
0929-5305
eISSN
1573-742X
DOI
10.1023/A:1011956703031
Publisher site
See Article on Publisher Site

Abstract

Background: Elevations in serum troponins among patients with acute coronary syndromes have been shown to identify those patients who are at high risk for poor outcome and who accrue larger relative benefits from aggressive antiplatelet and antithrombotic therapies. We studied a group of patients from the PRISM-PLUS trial to explore whether simply using serum troponin I, a serum marker of cardiac injury, could predict benefit of GP IIb/IIIa receptor antagonism with tirofiban.

Journal

Journal of Thrombosis and ThrombolysisSpringer Journals

Published: Oct 3, 2004

There are no references for this article.